On the afternoon of March 17, Yu Aihua, Member of the Standing Committee of the Provincial Party Committee and Secretary of the Municipal Party Committee, went to Hefei High-tech Zone to preach the spirit of the National Two Sessions, investigate the biopharmaceutical industry and grass-roots party building work, and coordinate on-site to help enterprises solve problems. Wu Lihua, director of the Provincial Drug Administration, and city leaders Shan Hu and Song Daojun attended the ceremony. Ms. Chen Fengling, general manager of DEEPBLUE Medical, and the heads of relevant departments warmly received and accompanied the visit and research.     Secretary Yu expressed strong interest in the New Coronavirus series testing products of different languages and specifications displayed by DEEPBUE Medical. Ms. Chen Fengling, general manager of DEEPBLUE Medical, introduced the self-developed New Coronavirus antigen detection reagents to Secretary Yu and his party by taking the product types and usage methods as the starting point. Secretary Yu fully affirmed and praised the development of DEEPBLUE Medical. After learning about the production and operation of DEEPBUE Medical in detail and experiencing the products on site, Secretary Yu Aihua attached great importance to discussing the trial of the New Coronavirus antigen product in Hefei with relevant departments on the spot, and requested the development and reform, Departments such as economics and information technology, science and technology and other departments will send personnel to station to help enterprises carry out registration application work. Ms. Chen Fengling, general manager of DEEPBLUE Medical, expressed her heartfelt thanks to the leaders of Secretary Yu and his party for their concern and support, and said that she would actively cooperate with relevant departments to complete the submission of application materials for the domestic listing registration certificate, promote the development of local medical and health services at a higher level, and serve the current severe epidemic situation. Contribute scientific research to the situation.

As a responsible and responsible enterprise, DEEPBLUE Medical has been actively repaying the society and continuously fulfilling its corporate citizenship responsibilities. DEEPBLUE Medical has been actively practicing corporate social responsibility for a long time, making continuous efforts in multiple dimensions, focusing on poverty alleviation, education, community, health and other directions, and integrating the core advantages and responsibilities of the enterprise into public welfare and charity. In the spring of 2020, a sudden epidemic disrupted people's lives and touched everyone's heart. Responsible enterprises and caring people from all walks of life have contributed to the prevention and control of the epidemic, and made concerted efforts with all the "guardians" who are fighting on the front line through various forms of donations to fight the epidemic. Bits of little love converge into a stream of warmth that warms people's hearts. In the fight against the epidemic, DEEPBLUE Medical continues to have caring tributaries to join in this "battle" to do their part to fight the epidemic. 1.Donate to Hong Kong On February 21, 2022, the Spring Festival was supposed to be full of flavor, but Hong Kong, China was shrouded in a severe pneumonia epidemic. Ms. Chen Fengling, general manager of DEEPBLUE Medical, actively fulfilled her social responsibilities, gathered strengths in the field to give full play to the industry's strengths, organized the company to donate 20 boxes of COVID-19 antigen front nose self-testing reagents to Hong Kong, and received them from the community in Hong Kong on March 10. Thank you letter from Anti-epidemic Connection. 2.Donate to King's College London In March 2020, DEEPBLUE Medical donated 10,000 SARS-CoV-2 (IgG/IgM) antibody detection kits to King's College London through Peking University HSBC Business School, and received a letter from Mr. Robert Lechler, Senior Vice President of King's College, UK. Thank you letter, the letter said: "One World, One Fight". DEEPBLUE Medical is proud to join hands with the United Kingdom to fight the epidemic, and is even more proud to receive a letter of thanks from Mr. Robert Lechler. 3.Donate to some schools in the province DEEPBLUE Medical donated hand sanitizer gel to Hefei High-tech Zone for use in school resumption. Donated hand sanitizer gel to the Feixi County Yandian Township Special Needs Support Center, Anhui Red Cross Fraternity School, Huangshan Jinchuan Middle School and Taihu Shahe Middle School for epidemic prevention and control. Deep Blue Medical cares about the elderly and children, and the elderly care center and school work together to fight the "epidemic". 4.Help Wuhan Epidemic Prevention and Control At the beginning of 2020, the new crown pneumonia epidemic broke out in Wuhan, Hubei Province for the first time. DEEPBLUE Medical responded quickly and started the donation process as soon as possible to make targeted donations to Wuhan Union Hospital in ...

The virus is ruthless, but there is love in the world. At present, in the tense battle of the whole people to fight against the COVID-19 epidemic, DEEPBLUE Medical donated the COVID-19 antigen detection kits, practiced its social responsibility with practical actions, reflected its mission, and helped the epidemic prevention and control work. In order to support Hefei's epidemic prevention and control work, on March 15th and 16th, DEEPBLUE Medical donated  COVID-19 antigen detection kits to the High-tech Zone Emergency Office and Luyang District Emergency Office respectively. The Municipal Red Cross Society donated 2 million copies of the COVID-19 antigen detection kits, explaining the responsibility and responsibility of enterprises with practical actions. In the current epidemic situation, fast words take the lead. In order to send the donated materials to various regions in Hefei as quickly as possible, DEEPBLUE Medical makes it play a role in the prevention and control of the epidemic. As soon as the donation ceremony is over, the deployment of donation matters will be started immediately. Efficiently complete the inventory and docking of donated products, so that each box of the COVID-19 antigen detection kits can exert the greatest value. On the evening of March 19, the staff of the Red Cross Society of Hefei came to the DEEPBLUE Medical Storage Center in Mingzhu Industrial Park to connect the distribution and transportation of reagents on site. The first batch of 430,000 the COVID-19 antigen detection kits were successively sent to Chaohu City, Lujiang County, Yaohai District, Baohe District, Shushan District and Luyang District. At 22 o'clock, the last anti-epidemic material transport vehicle left, and the friends of DEEPBLUE Medical temporarily relaxed their highly tense nerves. In the critical period of epidemic prevention and control, boxes of the COVID-19 antigen detection kits interpret the corporate responsibility and love of DEEPBLUE Medical. DEEPBLUE Medical uses practical actions to transmit positive social energy, and Hefei is more determined to win the epidemic. The battle of prevention and control has injected strong spiritual strength, fighting against the epidemic with everyone and protecting health and tranquility. In this battlefield without gunpowder smoke, DEEPBLUE Medical believes that by working together and united, we will be able to win the battle of epidemic prevention and control as soon as possible!

The donation of the third batch of 520,000 and the fourth batch of 547,000 the COVID-19 antigen detection kits by DEEPBLUE Medical came to an end when the last transport vehicle was ready to go on the afternoon of March 24. In just a few days, all the 2 million copies of the COVID-19 antigen test kits that DEEPBLUE Medical promised to donate have been donated, and will be distributed to all counties and districts in Hefei. Since the outbreak of the epidemic, DEEPBLUE Medical has been adhering to the mission and responsibility of the company, and has been paying close attention to the development of the epidemic and social needs. Local prevention and control agencies conduct epidemic prevention and control. This time, DEEPBLUE Medical donated 2 million the COVID-19 antigen detection reagents to the Hefei Red Cross Society, mainly to support Hefei's epidemic prevention and control work and build a strong line of defense. At present, the epidemic situation at home and abroad is still very serious. At this critical moment, we still need to be highly vigilant and not relax at all, whether it is the medical staff on the front line of the hospital, or the party members and volunteers in the community streets, or the workers who produce materials, and the prevention and control workers. Law enforcement police... The epidemic is not over yet, and DEEPBLUE  Medical's support will never stop. DEEPBLUE Medical will, as always, actively undertake social responsibilities, pay close attention to the development of the COVID-19 epidemic, fully support the epidemic prevention and control work, and continue to provide more help for epidemic prevention and control, and always do a good job with the anti-epidemic workers. Get ready to win this battle of epidemic prevention and control without gunpowder smoke together! DEEPBLUE Medical always believes that this "war epidemic" will eventually end, and all good things will come as promised.

On the morning of March 13, 2022, Ge Bin, member of the Standing Committee of the Hefei Municipal Party Committee, Executive Deputy Mayor, and related colleagues from the Health and Health Commission visited Anhui DEEPBLUE Medical Technology Co., Ltd. (hereinafter referred to as "DeepBlue Medical") to investigate and investigate the DEEPBLUE New Coronavirus antigen test Reagent development status. Mr. Zhang Chao, chairman of DEEPBLUE Medical, Ms. Chen Fengling, general manager, and the heads of relevant departments warmly received and accompanied the visit and research. Vice Mayor Ge and his entourage came to DEEPBLUE Medical located in Mingzhu Industrial Park and visited the automation workshop of DEEPBLUE Medical. During the visit, Zhang Chao, Chairman of DEEPBLUE, explained in detail the research and development process, production process and production capacity of the New Coronavirus antigen detection reagent. Afterwards, Chairman Zhang Chao reported to Vice Mayor Ge on the development and production and operation of the New Coronavirus antigen detection reagent under the new situation of DEEPBLUE Medical, and introduced in detail the research and development of the new coronavirus antigen detection reagent and the overseas listing process, and the products in the market. Clinical performance testing of overseas authoritative testing institutions, overseas product registration and export sales. Mayor Ge and his entourage fully affirmed and praised the development of DEEPBLUE Medical, and said that since the evening of March 11, the comprehensive team of the State Council's joint prevention and control mechanism for New coronavirus pneumonia decided to add antigen testing as a supplement on the basis of nucleic acid testing. After organizing and formulating the "New Coronavirus Antigen Detection Application Plan (Trial)", Hefei City is studying and formulating policies to promote the development of medical devices and biopharmaceutical industries, further improving the ability to serve enterprises, continuously optimizing the business environment, and helping enterprises in a timely manner. Solve the problems encountered in the development and provide good services for the development of the enterprise. According to the investigation conducted by Vice Mayor Ge and his delegation, Chairman Zhang Chao said that DEEPBLUE Medical is currently actively promoting the application for the registration certificate of the New Coronavirus antigen test in China, and will continue to innovate and reform in the future, strive to develop and produce better products, and further help The prevention and control of the New Coronavirus epidemic in the province has contributed to the economic development of Hefei City.

Recently, the National Standards Information Service Platform has released a list of 2019 standards issued by the China Institute for Food and Drug Control, the General Hospital of the Chinese People's Liberation Army, the Medical Device Technology Review Center of the State Drug Administration, the Beijing Institute of Medical Device Testing, and the Institute of Pathogen Biology, Chinese Academy of Medical Sciences. , "Quality Evaluation Requirements for Novel Coronavirus IgG Antibody Detection Kits" jointly drafted by 8 units of Zhuhai Livzon Reagent Co., Ltd., Boosaics (Chongqing) Biotechnology Co., Ltd., and Dana (Tianjin) Biotechnology Co., Ltd., Two national standards for "Quality Evaluation Requirements for Novel Coronavirus IgM Antibody Detection Kits". Standard task source The standard task comes from the National Standards Management Committee's "Notice on the issuance of 8 recommended national standards including "Quality Evaluation Requirements for Novel Coronavirus Nucleic Acid Detection Kits" (task number: 202001827-T-464); A large number of investigations were conducted to form a draft, and the Secretariat of the National Standardization Technical Committee for Medical Clinical Testing Laboratories and In Vitro Diagnostic Systems (SAC/TC136) and the Device Evaluation Center of the State Drug Administration were invited to clarify the relevant content. The significance of standard setting Up to now, more than 10 new coronavirus antibody IgM/IgG antibody detection kit products have been approved by my country's drug administration for the detection of antibodies in patients in the new coronavirus pneumonia epidemic. According to incomplete statistics, there are more than 30 A company has issued an EU CE self-conformity declaration. Therefore, related products are not only needed for the prevention and control of the new crown pneumonia epidemic at home and abroad, but also involve greater foreign economic and trade and the country's international responsibilities. Up to now, there is no standard for new coronavirus antibody detection products at home and abroad. The two national standards released this time are applicable to the production and quality evaluation of detection kits for the detection of 2019-nCoV antibodies in serum, plasma and whole blood samples. The evaluation requirements, test methods, packaging and transportation are specified in detail. By implementing the above two standards, the existing domestic new coronavirus detection products can be fully regulated, which will help to comprehensively evaluate the quality of the new coronavirus detection products to better meet the needs of clinical diagnosis. The standard will be officially implemented on March 1, 2022.

On October 28, 2021, the "DEEPBLUE" trademark of Anhui Deepblue Medical was successfully approved and protected by Austria. This is another milestone in the development history of Anhui Deepblue Medical, which marks that the Deepblue brand's strategy of going global has achieved remarkable results. We all know that trademarks are important intellectual property rights and high value-added intangible assets of enterprises, and trademarks are geographically restricted. A trademark registered in China can only mean that the trademark has exclusive rights in China. When the trademarked product is exported overseas , if there is no trademark "protective clothing" of the importing country, then the product of the trademark is not protected by the laws of that country. For Anhui Deepblue Medical, which has a long-term plan, the registration of international trademarks is a necessary strategic measure. The "DEEPBLUE" series products of Anhui Deepblue Medical have a high reputation in domestic and foreign markets in terms of quality and reputation. This time, the successful approval of Austrian protection not only improves the core competitiveness of the "DEEPBLUE" brand, but also lays the foundation for the higher-level strategic layout of Deepblue Medical.

On November 3, the good news of Deep Blue Medical - "DEEPBLUE" trademark was approved and protected by Bulgaria. This is another powerful tool for property rights protection obtained by "DEEPBLUE" after the recent approval of protection by Spain and Austria, and it is also another milestone towards the international market. With my country's entry into the WTO and the acceleration of Chinese enterprises' "going global" pace, the issue of international trademark protection has gradually emerged. Trademarks are an important part of an enterprise's intangible assets and comprehensive competitiveness. Deepblue Medical is well aware of the importance of trademark registration, so in the development strategy of Deepblue Medical, trademark protection occupies an important position. The implementation of the trademark strategy of Deepblue Medical is not only the internal driving force for the continuous expansion of scale, but also a strong guarantee for Deepblue Medical to enter the international market. As early as 2010, the company started to carry out trademark planning when it was first established. At present, it has 15 domestic trademarks. In 2020, the first batch of international trademark registrations will be registered through the Madrid system. In the international protection of the trademark of Deepblue Medical "DEEPBLUE", in addition to applying for trademark registration country by country, the Madrid trademark system is also an important way and means for Deepblue Medical to use it. With the approval and protection of many overseas countries, the global registration of the main brand trademark of "DEEPBLUE" has basically been realized, which has cleared the intellectual property obstacles for the future expansion of DeepBlue Medical's overseas business. Up to now, the company has carried out trademark registration work in more than 50 countries and regions around the world through the Madrid system and other organizations, basically covering the main overseas markets and potential markets of "DEEPBLUE".

On November 23, the good news came from Deepblue Medical that the "DEEPBLUE" international trademark was successfully approved and protected by France, Australia and the Czech Republic. The development of soft power will further promote the development of deep blue medical in foreign markets, create a deep blue brand, and improve the comprehensive competitiveness of Deepblue medical. In the international protection of the "DEEPBLUE" trademark, in addition to applying for trademark registration country by country, the Madrid international trademark registration system is an important way and means for brands to borrow. The Madrid System is a solution for global trademark registration and management. Through a centralized system, trademarks can not only apply for protection in up to 120 countries, but also change, renew or expand global trademarks. Up to now, the "DEEPBLUE" brand trademark has obtained trademark exclusive rights in 20 countries including Italy, the Netherlands, Germany, Spain, Austria, and Bulgaria, and has continuously extended the exclusive rights to other member states of the Madrid System. In the next step, Deepblue Medical will continue to strengthen the company's trademark reserve and management level based on the company's advantages, apply for trademark registration in advance according to business development and corporate planning, and prepare for the listing of Deepblue products, corporate brand building, and image enhancement. The market offers more opportunities.

Trademarks are an important part of an enterprise's intangible assets and comprehensive competitiveness. At present, Deepblue Medical's Chinese, English and graphic trademarks have all applied for registration protection, effectively protecting the company's intangible assets and legitimate rights and interests. Over the years, the company has continued to explore the international market, and the number of countries and regions for product export has continued to increase. In order to further protect the company’s rights and interests in the international market, the company has continued to expand its brand influence and market share. In 2020, Deepblue Medical carried out trademark protection in various countries through the Madrid trademark system, and successively received approval and protection. On December 15, DEEPBLUE obtained the approval protection notice from the Slovak State. The successful acquisition of Slovakia’s approval and protection this time is an important step and result of Deepblue Medical’s establishment of a global brand. It is also a strong guarantee for the protection of the exclusive rights of Deepblue Medical’s overseas trademarks. It is a milestone for Deepblue’s future development and is a brand competition for Deepblue. It has laid a solid foundation for achieving innovation-driven, boosting the development of foreign markets, creating high-quality brands, and achieving higher-level development.